Phase II study of combined administration of 5-fluorouracil, epirubicin and mitomycin-C by hepatic artery infusion in patients with liver metastases of gastric cancer

Oncology

Volumn 57, Issue 3, 1999, Pages 216-223

  Kumada, Takashi ^a   Arai, Yasuaki ^b   Itoh, Kazuki ^c   Takayasu, Yukio ^d   Nakamura, Kenji ^e   Ariyoshi, Yutaka ^b   Tajima, Kazuo ^b  

^a OGAKI MUNICIPAL HOSPITAL   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

^c SHIZUOKA GENERAL HOSPITAL   (Japan)

^d HYOGO COLLEGE OF MEDICINE   (Japan)

^e Osaka Prefecture University   (Japan)

Author keywords

FEM; Gastric cancer; Hepatic arterial infusion; Liver metastases

Indexed keywords

EPIRUBICIN; FLUOROURACIL; MITOMYCIN C;

ADULT; AGED; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL TRIAL; FEMALE; HEPATIC ARTERY; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; IRON DEFICIENCY ANEMIA; LEUKOPENIA; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; STOMACH CANCER; SURVIVAL RATE; THROMBOCYTOPENIA; VOMITING;

AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; EPIRUBICIN; FEMALE; FLUOROURACIL; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; JAPAN; LIVER NEOPLASMS; MALE; MIDDLE AGED; MITOMYCIN; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0032861226     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000012034     Document Type: Article

References (33)

1. Aoki K: Epidemiology of stomach cancer; in Nishi M, Ichikawa H, Nakajima T, Maruyama K, Tahara E (eds): Gastric Cancer. Tokyo, Springer, 1993, pp 2-15.
2. Hisamiti S, Fukao A, Tsubono Y: Evaluation of mass screening for stomach cancer; in Nishi M, Ichikawa H, Nakajima T, Maruyama K, Tahara E (eds): Gastric Cancer. Tokyo, Springer, 1993, pp 16-25.
3. Yonemura Y, Ohyama S, Kamata T, Fujimura T, Kimura H, Matsuki N, Sakuma H, Sawa T, Katayama K, Hasegawaet H, Kosaka T, Yamaguti A, Miwa K, Miyazaki I: Multivariate analysis of gastric cancer patients with liver metastases. Jpn J Cancer Chemother 1990;17:2063-2069.
4. Arai Y, Endo T, Sone Y, Tohyama N, Inaba Y, Ariyoshi Y, Kido C: Management of patients with unresectable liver metastases from colorectal and gastric cancer employing an implantable port system. Cancer Chemother Pharmacoll 1992;31(suppl I):S99-S102.
5. Preusser P, Achterrath W, Wilke H, Lenaz L, Fink U, Heinicke H, Meyer J, Bunter H: Chemotherapy of gastric cancer. Cancer Treat Rev 1988;15:257-277.
6. Yonemura Y, Matsuki N, Sakuma H, Katayama K, Sawa T, Fujimura T, Ohyama S, Miwa K, Miyazaki I, Tanaka M, Sasaki T: Effect of intra-hepatoarterial infusion of MMC and CDDP for gastric cancer patients with liver metastases. Surg Today 1992;22:253-259.
7. Japan Society for Cancer Therapy: Criteria for the evaluation of the clinical effects of solid cancer chemotherapy. J Jpn Soc Cancer Ther 1986;21:929-942.
8. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 1981;47:207-214.
9. Cunningham D: Gastric cancer - The recognition of a chemosensitive tumour. Br J Cancer 1988;58:695-699.
10. MacDonald JS, Woolley PV, Smythe T, Ueno W, Hoth D, Schein PS: 5-Fluorouracil, Adriamycin, and mitomycin-C (FAM) combination chemotherapy in the treatment of advanced gastric cancer. Cancer 1979;44:42-47.
11. Cunningham D, Soukop M, McArdle CS, Carter DC, Smyth JF: Advanced gastric cancer: Experience in Scotland using 5-fluorouracil, Adriamycin and mitomycin-C. Br J Surg 1984; 71:673-676.
12. Wagener DJ, Yap SH, Wobbes T, Burghouts JT, Dam Van FE, Hillen HF, Hoogendoorn GJ, Scheerder H, von der Vegt SGL: Phase II trial of 5-fluorouracil, Adriamycin and cisplatin (FAP) in advanced gastric cancer. Cancer Chemother Pharmacol 1985;15:86-87.
13. Moertel CG, Rubin J, O'Connell MJ, Schutt AJ, Wieand HA: A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinoma. J Clin Oncol 1986;4: 1053-1057.
14. Wils J, Bleiberg H, Dalesio O, Blijham G, Mulder N, Planting A, Splinter T, Duez N: An EORTC Gastrointestinal Group evaluation of the combination of sequential methotrexate and 5-fluorouracil, combined with Adriamycin in advanced measurable gastric cancer. J Clin Oncol 1986;4:1799-1803.
15. Wils JA, Klein HO, Wagener DJ, Bleiberg H, Reis H, Korsten F, Conroy T, Fickers M, Leyvraz S, Buyse M, Duez N: Sequential high-dose methotrexate and fluorouracil combined with doxorubicin - A step ahead in the treatment of advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 1991;9:827-831.
16. Preusser P, Wilke H, Achterrath W, Fink U, Lenaz L, Heinicke A, Meyer J, Meyer H-J, Buente H: Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol 1989;7:1310-1317.
17. Katz A, Gansl RC, Simon SD, Gama-Rodrigues J, Waitzberg D, Bresciani C, Pinotti HW: Phase II trial of etoposide (V), Adriamycin (A), and cisplatinum (P) in patients with metastatic gastric cancer. Am J Clin Oncol 1991;14:357-358.
18. Rath U, Flechtner H, Selbach J, Harjung H, Manegold C, Kalbelitz K, Trux FA, Edler L, Schlag P, Queisser W: Etoposide, Adriamycin, and cisplatinum (EAP) combination chemotherapy for advanced gastric cancer. A phase II trial by the 'Chemotherapiegruppe Gastrointestinaler Tumoren (CGT)'. Onkologie 1990; 13:194-197.
19. Wilke H, Preusser P, Stahl M, Harstrik A, Meyer HJ, Achterrth W, Schmoll HJ, Seeber S: Etoposide, folinic acid, and 5-fluorouracil in carboplatin-pretreated patients with advanced gastric cancer. Cancer Chemother Pharmacol 1991;29:83-84.
20. Stahl M, Wilke H, Preusser P, Fink U, Achtenath W, Schober C, Kohne-Wompner CH, Harstrik A, Meyer HJ, Meyer J, Lenaz L, Schmoll HJ: Etoposide, leucovorin and 5-fluorouracil (ELF) in advanced gastric carcinoma - Final results of a phase II study in elderly or patients with cardiac risk. Onkologie 1991;14:314-318.
21. Lacave AJ, Baron FJ, Anton LM, Estrada E, De Sande LM, Palacio I, Esleban E, Gracia JM, Buesa JM, Fernandes OA, Baron MG: Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer A phase II trial. Ann Oncol 1991;2:751-754.
22. Findlay M, Mansi JL, Ford HT, Nash AT, Cunningham D: Epirubicin, cisplatin and 5-fluorouracil (ECF) is highly effective in advanced gastric cancer (abstract). Eur J Cancer 1991;(suppl 2):71.
23. Villar-Grimalt A, Candel MT, Garcia J, Bernacer B, Jimero J: Combination of etoposide, Adriamycin and cisplatin (EAP) in gastric cancer: Association with severe toxicity. Ann Oncol 1991;2:310-311.
24. Kemeny N, Daly J, Reichman B, Geller N, Botet J, Oderman P: Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med 1987;107: 459-465.
25. Chang AE, Schneider P, Sugarbaker PH, Simpson C, Culnane M, Steinberg S: A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 1987;206:685-693.
26. Hohn DC, Stagg RJ, Friedman MA, Hannigan JF, Rayner A, Ignoffo RJ, Acord P, Lewis BJ: A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: The Northern California Oncology Group Trial. J Clin Oncol 1989;7:1646-1654.
27. Martin JK Jr, O'Connell MJ, Wieand HS, Fitzgibbons RJ Jr, Mailliard JA, Rubin J, Nagorney DM, Tschetter LK, Krook JE: Intra-arterial floxuridine vs. systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. Arch Surg 1990;125:1022-1027.
28. Rougier P, Laplanche A, Huguier M, Hay J, Ollivier JM, Escot J, Salmon R, Julien M, Audy JCR, Gallot D, Gouzi JL, Pailler JL, Elisa D, Lacaine F, Roos S, Rotman N, Luboinski M, Lasser P: Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: Long-term results of a prospective randomized trial. J Clin Oncol 1992; 10:1112-1118.
29. Safi F, Bittner R, Roscher R, Schuhmacher K, Gaus W, Berger GH: Regional chemotherapy for hepatic metastases of colorectal carcinoma (continuous intraarterial versus continuous intraarterial/intravenous therapy). Results of a controlled clinical trial. Cancer 1989;64:379-387.
30. Lorenz M, Hottenrott C, Inglis R, KirkowaReimann M: Prevention of extrahepatic disease during intraarterial floxuridine of colorectal liver metastases by simultaneous systemic 5-fluorouracil treatment? A prospective multicenter study. Jpn J Cancer Chemother 1989; 16:3662-3671.
31. Wiley AL Jr, Wirtanen GW, Stephenson JA, Ramirez G, Dements D, Lee JW: Combined hepatic artery 5-fluorouracil and irradiation of liver metastases. A randomized study. Cancer 1989;64:1783-1789.
32. Kemeny N, Conti JA, Sigurdson E, Cohen A, Seiter K, Lincer R, Niedzwiecki D, Botet J, Chapman D, Costa P, Budd A: A pilot study of hepatic artery floxuridine combined with systemic 5-fluorouracil and leucovorin. A potential adjuvant program after resection of colorectal hepatic metastases. Cancer 1993;71: 1964-1971.
33. Arai Y, Inaba Y, Takeuchi Y: Part 6. Interventional techniques for hepatic arterial infusion chemotherapy; in Wilfrido R, Castaneda-Zuniga (eds): Interventional Radiology. Tokyo, Williams & Wilkins, 1997,pp 192-205.